218 related articles for article (PubMed ID: 10470083)
1. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs.
Schuetz JD; Connelly MC; Sun D; Paibir SG; Flynn PM; Srinivas RV; Kumar A; Fridland A
Nat Med; 1999 Sep; 5(9):1048-51. PubMed ID: 10470083
[TBL] [Abstract][Full Text] [Related]
2. Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4.
Clemente MI; Alvarez S; Serramía MJ; Turriziani O; Genebat M; Leal M; Fresno M; Muñoz-Fernández MA
Antivir Ther; 2009; 14(8):1101-11. PubMed ID: 20032540
[TBL] [Abstract][Full Text] [Related]
3. A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent.
Robbins BL; Connelly MC; Marshall DR; Srinivas RV; Fridland A
Mol Pharmacol; 1995 Feb; 47(2):391-7. PubMed ID: 7870049
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microglia.
Dallas S; Schlichter L; Bendayan R
J Pharmacol Exp Ther; 2004 Jun; 309(3):1221-9. PubMed ID: 14762102
[TBL] [Abstract][Full Text] [Related]
5. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
6. Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals.
Gallego O; Martin-Carbonero L; Aguero J; de Mendoza C; Corral A; Soriano V
J Virol Methods; 2004 Oct; 121(1):115-8. PubMed ID: 15350741
[TBL] [Abstract][Full Text] [Related]
7. Selection of a T-cell line resistant to stavudine and zidovudine by prolonged treatment with stavudine.
Turriziani O; Scagnolari C; Bambacioni F; Bellomi F; Focher F; Gentile M; Antonelli G
Antivir Ther; 2002 Jun; 7(2):105-11. PubMed ID: 12212922
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out?
Naeger LK; Miller MD
Curr Opin Investig Drugs; 2001 Mar; 2(3):335-9. PubMed ID: 11575701
[TBL] [Abstract][Full Text] [Related]
9. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.
Miller MD; Margot NA; Hertogs K; Larder B; Miller V
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1025-8. PubMed ID: 11562951
[TBL] [Abstract][Full Text] [Related]
10. Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates.
Gong YF; Marshall DR; Srinivas RV; Fridland A
Antimicrob Agents Chemother; 1994 Jul; 38(7):1683-7. PubMed ID: 7979311
[TBL] [Abstract][Full Text] [Related]
11. 6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4.
Janke D; Mehralivand S; Strand D; Gödtel-Armbrust U; Habermeier A; Gradhand U; Fischer C; Toliat MR; Fritz P; Zanger UM; Schwab M; Fromm MF; Nürnberg P; Wojnowski L; Closs EI; Lang T
Hum Mutat; 2008 May; 29(5):659-69. PubMed ID: 18300232
[TBL] [Abstract][Full Text] [Related]
12. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
13. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
Foli A; Sogocio KM; Anderson B; Kavlick M; Saville MW; Wainberg MA; Gu Z; Cherrington JM; Mitsuya H; Yarchoan R
Antiviral Res; 1996 Oct; 32(2):91-8. PubMed ID: 8891168
[TBL] [Abstract][Full Text] [Related]
14. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.
Gu Z; Salomon H; Cherrington JM; Mulato AS; Chen MS; Yarchoan R; Foli A; Sogocio KM; Wainberg MA
Antimicrob Agents Chemother; 1995 Aug; 39(8):1888-91. PubMed ID: 7486942
[TBL] [Abstract][Full Text] [Related]
15. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
Ross L; Johnson M; Graham N; Shaefer M; St Clair M
J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates.
Mackman RL; Boojamra CG; Prasad V; Zhang L; Lin KY; Petrakovsky O; Babusis D; Chen J; Douglas J; Grant D; Hui HC; Kim CU; Markevitch DY; Vela J; Ray A; Cihlar T
Bioorg Med Chem Lett; 2007 Dec; 17(24):6785-9. PubMed ID: 18029175
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage.
Belinsky MG; Guo P; Lee K; Zhou F; Kotova E; Grinberg A; Westphal H; Shchaveleva I; Klein-Szanto A; Gallo JM; Kruh GD
Cancer Res; 2007 Jan; 67(1):262-8. PubMed ID: 17210706
[TBL] [Abstract][Full Text] [Related]
18. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.
Harris KS; Brabant W; Styrchak S; Gall A; Daifuku R
Antiviral Res; 2005 Jul; 67(1):1-9. PubMed ID: 15890415
[TBL] [Abstract][Full Text] [Related]
19. l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance.
Chong Y; Gumina G; Mathew JS; Schinazi RF; Chu CK
J Med Chem; 2003 Jul; 46(15):3245-56. PubMed ID: 12852755
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5.
Reid G; Wielinga P; Zelcer N; De Haas M; Van Deemter L; Wijnholds J; Balzarini J; Borst P
Mol Pharmacol; 2003 May; 63(5):1094-103. PubMed ID: 12695538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
